Novo Nordisk launches higher-dose Wegovy in the US to improve weight-loss results.

Novo Nordisk has launched a higher-dose version of its weight-loss drug Wegovy in the United States, aiming to enhance weight-loss results for patients. The new formulation builds on the drug's existing reputation for treating obesity and overweight conditions. The launch follows clinical trials demonstrating improved efficacy and safety at the higher dosage. This move reflects broader industry trends toward personalized treatments for metabolic conditions and comes amid rising demand for obesity therapies.